Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

This is why I think BMY will not acquire nor make any cash deals with ADXS, at least, within a year or two. They just spent $74B to acquire CELG, and will be busy digesting that beast. Also, CAR-T that was almost certainly considered a no-go for solid tumors now is back in the game. Advaxis keeps falling back and the tech get more and more obsolete as the company moves at a snail's speed.


Bristol-Myers drives into CAR-T therapies
https://www.eiu.com/industry/article/817665265/bristol-myers-drives-into-car-t-therapies/2019-02-18

snips:
Yet despite these challenges, competition in the CAR-T field is increasing. As well as Bristol-Myers, Kite, Gilead and Novartis, other new entrants include AbbVie. In mid-2018 it announced collaboration with the California Institute for Biomedical Research (Calibr) for next-generation CAR-T therapies, this time focused directly on solid tumours. The immuno-oncology push will be even more important for AbbVie after the failure of Rova-T, a major cancer drug candidate, in late-stage clinical trials.

Despite these potential rivals, it is Bristol-Myers that is now forging ahead into the CAR-T field. With the help of Cellgene, it already claims to be among the top five companies in terms of immunology and inflammation. And if CAR-T ever lives up to its promise, the US company is primed.